Abstract

Osimertinib is a third generation Tyrosine Kinase Inhibitor (TKI) and is considered first line therapy for patients with metastatic Epidermal Growth Factor Receptor (EGFR) NSCLC with exon 19 deletion or exon 21 L858R. Osimertinib has demonstrated improved progression free survival (PFS) and overall survival (OS) compared to first generation TKI’s. However, during the course of their disease many patients develop oligoprogressive disease (OPD): <=3 metastatic lesions with otherwise controlled systemic disease.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call